Filing Flows › Neogenomics (NEO) › Q1 2026
Neogenomics (NEO) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 28, 2026
Neogenomics (NEO) reported revenue of $187M for the first quarter 2026 (Q1 2026), +11% from a year earlier and -2% from the quarter before. Operating margin was -9.8%, net loss $17.1M (9.2% of revenue).
Neogenomics, Q1 2026: revenue $187M (+11% year over year), operating margin -9.8%, net loss $17.1M, operating cash flow −$8.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $187M | -2% | +11% |
| Operating profit | −$18.2M | — | — |
| Net earnings | −$17.1M | — | — |
| Operating cash flow | −$8.1M | -706% | — |
What changed
Revenue was $186.7M in Q1 2026, up 11% year over year and down 2% from the previous quarter. Client direct billing was the largest line at 71% of revenue. Client direct billing added $9.6M year over year (up 8%), 51% of the total change.
Gross margin was 43.3%, down 0.3 points from Q1 2025. Operating costs exceeded revenue by $18.2M, an operating margin of -9.8%. Operating expenses fell 2% while revenue rose 11%. The quarter ended with a net loss of $17.1M, wider than the previous quarter's $9.9M loss.
Operating cash flow was −$8.1M. Non-cash charges added back $16.4M of depreciation and amortization and $9.6M of share-based compensation. Working capital and other items used $17.1M. Capital expenditures of $5.0M exceeded it, leaving free cash flow of −$13.1M.
Questions
What was Neogenomics' revenue in the first quarter 2026?
Neogenomics (NEO) reported revenue of $187M for the first quarter 2026 (Q1 2026), +11% from a year earlier and -2% from the quarter before.
Was Neogenomics profitable in the first quarter 2026?
Operating loss was $18.2M (-9.8% of revenue) and net loss $17.1M.
Source: Neogenomics 10-Q on SEC EDGAR.